PRINCETON, NJ – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has conditionally accepted HyBryte™ as the proposed brand...
Latest News
PRINCETON, N.J. — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in...
BARCELONA, Spain – SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, today announces that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on granting Orphan Drug Designation (ODD) for SOM3355 for...
Nagoya, Japan – An international team, led by researchers at Nagoya University in Japan, may have determined why the diffuse anaplasia (DA) subtype of Wilms tumor (WT) resists chemotherapy. This subtype grows even when it has a high burden of DNA damage and increases the mutation rate of tumor protein...
He is just eight years old and should be enjoying football and computer games. But Ben Scott suffers from a rare form of dementia – which is slowly robbing him of his mental faculties and taking his life away. He can still recognise his mum and dad and give them...
OAKLAND, Calif. — SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 (aminolevulinic acid HCl) in combination with Insightec’s Exablate 4000 Type-2 ultrasound device today announced the presentation of positive preliminary data from the ongoing Phase 1/2 SDT-201 study in Diffuse Intrinsic Pontine Glioma (DIPG). These...
WATERTOWN, Mass. — Sonata Therapeutics, a biotechnology company developing a new class of therapeutics called Network Medicines™, and the Champalimaud Foundation, a world leader in biomedical research and academic medicine, today announced a research collaboration for the development of Sonata’s novel Network Medicine, SNT-3012. The partnership will drive the continued...
SOUTH SAN FRANCISCO, Calif. — SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the American Society of Nephrology’s annual meeting being held November 5-9 in Houston, Texas. The poster presentation focuses...
BOSTON, Mass. and ROLLE, Switzerland – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results...
Beijing, China – Hepatocellular carcinoma (HCC) is a common disease in human history and one of the main causes of cancer-related death. Sorafenib (SORA) is the best representative of angiogenesis inhibitors and is currently being commonly used in the treatment of advanced HCC as a first-line drug. Although SORA improves...